Management of New Left Bundle Branch Block
Initial Evaluation
- The American College of Cardiology recommends transthoracic echocardiography as a Class I recommendation (Level of Evidence: B-NR) for all patients with newly detected LBBB to assess for structural heart disease and left ventricular function 1, 2, 3
- Laboratory testing based on clinical suspicion is reasonable (Class IIa, Level of Evidence: C-LD) to identify potential underlying causes, such as abnormal blood test results 1, 2
- Advanced imaging (cardiac MRI, CT, or nuclear studies) is reasonable (Class IIa, Level of Evidence: C-LD) in cases where echocardiography is unrevealing but structural heart disease is still suspected 3
- Stress testing with imaging may be considered if ischemic heart disease is suspected 3
Risk Stratification and Monitoring
- Ambulatory electrocardiographic monitoring is useful to detect potential intermittent atrioventricular block (Class I, Level of Evidence: C-LD) in symptomatic patients with LBBB, such as those experiencing dizziness or fainting 3, 4
- Electrophysiology study (EPS) is reasonable in patients with symptoms suggestive of intermittent bradycardia with conduction system disease identified by ECG (Class IIa, Level of Evidence: B-NR) 3
Indications for Permanent Pacing
- Permanent pacing is recommended for patients with LBBB and syncope who are found to have an HV interval ≥70 ms or evidence of infranodal block at EPS (Class I, Level of Evidence: B-NR) 5, 6
- Permanent pacing is recommended for patients with alternating bundle branch block due to high risk of developing complete AV block (Class I, Level of Evidence: C-LD) 5, 6, 7
- For patients with specific disorders associated with LBBB, such as Kearns-Sayre syndrome, permanent pacing is reasonable, with additional defibrillator capability if appropriate (Class IIa, Level of Evidence: C-LD) 5, 7
- Cardiac resynchronization therapy (CRT) may be considered in patients with heart failure, mildly to moderately reduced LVEF, and LBBB with QRS ≥150 ms (Class IIb, Level of Evidence: C-LD) 5, 7